Compare CACI & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CACI | ELAN |
|---|---|---|
| Founded | 1962 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 12.7B |
| IPO Year | 2007 | 2018 |
| Metric | CACI | ELAN |
|---|---|---|
| Price | $520.20 | $23.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $673.00 | $27.89 |
| AVG Volume (30 Days) | 205.2K | ★ 4.3M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 11.22 | N/A |
| Revenue | $4,467,860,000.00 | ★ $4,715,000,000.00 |
| Revenue This Year | $12.42 | $8.21 |
| Revenue Next Year | $10.00 | $5.31 |
| P/E Ratio | $46.84 | ★ N/A |
| Revenue Growth | 2.60 | ★ 6.22 |
| 52 Week Low | $409.62 | $8.59 |
| 52 Week High | $683.50 | $27.72 |
| Indicator | CACI | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 48.86 |
| Support Level | $499.81 | $22.17 |
| Resistance Level | $537.69 | $23.70 |
| Average True Range (ATR) | 20.06 | 0.90 |
| MACD | -3.52 | 0.05 |
| Stochastic Oscillator | 0.72 | 63.87 |
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.